Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in J Neurol Retrieve available abstracts of 108 articles: HTML format

Single Articles

October 2026
1. CHEN Y, Tong Z, Wang H, Xu X, et al
   Dynamic long-term modulation of cognition, brain structure and covariance networks in mild cognitive impairment due to AD by donepezil: A 36-month longitudinal study.
   J Neurol. 2026;273:677.
   PubMed     Abstract available
   
   
   
2. WU Y, Zhu L, Chen J, Liu J, et al
   Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis.
   J Neurol. 2026;273:675.
   PubMed     Abstract available
   
   
   
3. LIN YS, Tsai MJ, Lai CL, Ho HL, et al
   Clinical performance and decision thresholds of an automated plasma p-tau217 assay for amyloid pathology in a Taiwanese memory clinic.
   J Neurol. 2026;273:674.
   PubMed     Abstract available
   
   
   
4. STAPF CD, Uzelac Z, Iterbeke L, Guthknecht A, et al
   Serum p-tau181 and p-tau217 levels in adolescents and adults with 5q spinal muscular atrophy.
   J Neurol. 2026;273:672.
   PubMed     Abstract available
   
   
   
5. ZILIOLI A, Mohanty R, Rosenberg A, Matton A, et al
   Cortical thickness signature of early-onset Alzheimer's disease across clinical stages and A/T1 biomarker profiles.
   J Neurol. 2026;273:646.
   PubMed     Abstract available
   
   
   
6. BAUN AM, Iranzo A, Terkelsen MH, Hinz R, et al
   Multimodal PET-MRI profiling predicts dementia with Lewy bodies in isolated REM sleep behaviour disorder.
   J Neurol. 2026;273:635.
   PubMed     Abstract available
   
   
   September 2026
7. MCCANN E, Coleman F, Lee S, Fazlollahi A, et al
   Dorsal and ventral stream visuoperceptual processing deficits in Lewy body disease.
   J Neurol. 2026;273:620.
   PubMed     Abstract available
   
   
   
8. FERNANDEZ A, Molanes-Lopez EM, Zuluaga P, Vaquero L, et al
   The link between plasma and cognitive markers for Alzheimer's disease in Down syndrome: a longitudinal study.
   J Neurol. 2026;273:619.
   PubMed     Abstract available
   
   
   
9. OWEN AM
   What have trials targeting amyloid in Alzheimer's told us to date? The conversation the Alzheimer's field isn't having.
   J Neurol. 2026;273:617.
   PubMed     Abstract available
   
   
   
10. CHEN T, Sun Q, Foxe D, Narasimhan M, et al
    Behavioural and psychological symptom determinants of carer burden across clinical syndromes associated with frontotemporal lobar degeneration and Alzheimer's disease: a transdiagnostic analysis.
    J Neurol. 2026;273:592.
    PubMed     Abstract available
    
    
    
11. AIELLO EN, Canu E, Castelnovo V, Frisco F, et al
    Discriminating behavioral variant frontotemporal dementia from Alzheimer's disease via the Frontal Assessment Battery.
    J Neurol. 2026;273:585.
    PubMed     Abstract available
    
    
    
12. ELGENIDI A, Shir D, Piura YD, Sokol LL, et al
    Prion disease mimicking rapidly progressive Alzheimer disease: case series and systematic review.
    J Neurol. 2026;273:565.
    PubMed     Abstract available
    
    
    
13. HOLLEMAN J, Kareholt I, Nasholm MS, Sorensen C, et al
    Insomnia symptoms and stress exposure interact in relation to Alzheimer's disease biomarkers.
    J Neurol. 2026;273:560.
    PubMed     Abstract available
    
    
    July 2026
14. YAO Q, Han X, Cui T, Li D, et al
    Serial failure of the brain clearance continuum in Alzheimer's disease: mechanisms and therapeutic perspectives.
    J Neurol. 2026;273:480.
    PubMed     Abstract available
    
    
    
15. KWON HS, Moon SY, Hwang M, Kim HJ, et al
    Blood-based multimodal biomarker models for differentiating early-onset Alzheimer's disease from frontotemporal dementia: a longitudinal study of early-onset dementia and family members (LEAF) study.
    J Neurol. 2026;273:474.
    PubMed     Abstract available
    
    
    
16. PETERSEN CE, Damsgaard L, Janbek J, Laursen TM, et al
    Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.
    J Neurol. 2026;273:443.
    PubMed     Abstract available
    
    
    
17. SPALLAZZI M, Zilioli A, Ruffini L, Imbimbo BP, et al
    Number needed to treat and harm for lecanemab and donanemab in early Alzheimer disease.
    J Neurol. 2026;273:436.
    PubMed    
    
    
    June 2026
18. CHEN Y, Wang Z, Chen H, Li H, et al
    Plasma p-Tau217 and Abeta42/Abeta40 mediate the association between minimal depressive symptoms and cognitive impairment.
    J Neurol. 2026;273:409.
    PubMed     Abstract available
    
    
    May 2026
19. IHARA Y, Miyaue N, Ihara M, Kurata T, et al
    Association of probiotic medication use with incident Parkinson disease and alzheimer disease: a nationwide nested case-control study.
    J Neurol. 2026;273:349.
    PubMed     Abstract available
    
    
    
20. MORBELLI SD, Bozzali M, Cagnin A, Cecchin D, et al
    Precision pathways: optimising amyloid PET for sustainable Alzheimer's disease care.
    J Neurol. 2026;273:340.
    PubMed     Abstract available
    
    
    
21. POLI M, Bonomi CG, Di Donna MG, Barberis I, et al
    Streamlining Alzheimer's disease diagnosis: real-world validation of two-cut-off diagnostic models based on plasma p-tau/Abeta42 ratios.
    J Neurol. 2026;273:306.
    PubMed     Abstract available
    
    
    
22. HAFEZ MM, Abbas HA, Shoman NA, Soubh AA, et al
    A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease.
    J Neurol. 2026;273:303.
    PubMed     Abstract available
    
    
    April 2026
23. BRIEL N, Borsi M, Schreiner SJ, Schneider T, et al
    Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology.
    J Neurol. 2026;273:296.
    PubMed     Abstract available
    
    
    
24. GUO J, Yang Z, Luo S, Li C, et al
    Alzheimer's disease: disrupted communication between the endoplasmic reticulum and mitochondria.
    J Neurol. 2026;273:283.
    PubMed     Abstract available
    
    
    March 2026
25. VRILLON A, Gotze K, Dumurgier J, Cognat E, et al
    Eligibility for lecanemab treatment in a French memory clinic setting.
    J Neurol. 2026;273:228.
    PubMed     Abstract available
    
    
    
26. CHEN Y, Wang Z, Chen H, Cui H, et al
    Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer's disease.
    J Neurol. 2026;273:183.
    PubMed     Abstract available
    
    
    February 2026
27. BAMFORD AR, Logan C, Do QT, Nguyen K, et al
    Salivary total tau: a clinically practical measure of tau neuropathology in Alzheimer's disease.
    J Neurol. 2026;273:149.
    PubMed     Abstract available
    
    
    
28. MATIAS-GUIU JA, Ortega-Madueno I, Gil-Moreno MJ, Cardenas MC, et al
    Impact of blood p-tau217 testing on diagnosis and diagnostic confidence in cognitive disorders: a real-world clinical study.
    J Neurol. 2026;273:130.
    PubMed     Abstract available
    
    
    
29. XIONG D, Liu M, Liu Z, Wang J, et al
    Integrating standard and native spaces for radiomics and brain network analysis in Alzheimer's disease diagnosis and prognosis.
    J Neurol. 2026;273:124.
    PubMed     Abstract available
    
    
    January 2026
30. CECCHINI MA, Studart-Neto A, Moraes NC, Carneiro CG, et al
    Short-term memory conjunctive binding in subjective cognitive decline: A PET biomarker-based study.
    J Neurol. 2026;273:107.
    PubMed     Abstract available
    
    
    
31. HAFNER F, Bernhardt A, Goldschagg N, Hopfner F, et al
    Dementia with lewy bodies and Alzheimer s Disease overlap syndrome with PSP-like phenotype caused by co-pathologies - a case report.
    J Neurol. 2026;273:62.
    PubMed    
    
    
    December 2025
32. KAC PR, Gonzalez-Escalante A, Mila-Aloma M, Ashton NJ, et al
    Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-beta pathology.
    J Neurol. 2025;273:48.
    PubMed     Abstract available
    
    
    
33. OZLU S, Dyrba M, Grazia A, Brosseron F, et al
    CSF biomarkers of neuroinflammation are associated with regional atrophy.
    J Neurol. 2025;273:46.
    PubMed     Abstract available
    
    
    
34. DUAN X, Wang F, Liu W, Xie Y, et al
    The diagnostic value of plasma Abeta42 and Abeta40 in Alzheimer's disease: current status, challenges, and impacting variables.
    J Neurol. 2025;273:30.
    PubMed     Abstract available
    
    
    
35. GUILLEN N, Esteller D, Sarto J, Perales I, et al
    Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer's disease.
    J Neurol. 2025;273:28.
    PubMed     Abstract available
    
    
    
36. NA S, Muir K, Lophatananon A, Huang Y, et al
    Physical activity and Alzheimer's disease risk across genetic susceptibility: a prospective UK Biobank study using accelerometer data.
    J Neurol. 2025;273:1.
    PubMed     Abstract available
    
    
    November 2025
37. BUONOCORE J, Fratto E, Arcuri F, Vescio B, et al
    Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank.
    J Neurol. 2025;272:755.
    PubMed     Abstract available
    
    
    
38. NOLI B, Muqaku B, Gouda M, Manai AL, et al
    VGF AQEE- and GGEE-peptides differentiate between dementia types.
    J Neurol. 2025;272:745.
    PubMed     Abstract available
    
    
    October 2025
39. GUO X, Yue R, Cui Z, Wang S, et al
    Advances of therapeutic strategies for Alzheimer's disease.
    J Neurol. 2025;272:705.
    PubMed     Abstract available
    
    
    
40. HUANG XT, Huang LY, Tan CC, Wei JM, et al
    The role of APOE epsilon4 in modulating the relationship between non-genetic risk factors and dementia: a system review and meta-analysis.
    J Neurol. 2025;272:690.
    PubMed     Abstract available
    
    
    
41. ELKANA O, Beheshti I
    Brain age as an accurate biomarker of preclinical cognitive decline: evidence from a 12-year longitudinal study.
    J Neurol. 2025;272:672.
    PubMed     Abstract available
    
    
    
42. WADOP YN, Bernal R, Njamnshi WY, Satizabal CL, et al
    Altered gut microbiota mediates the association between APOE genotype and amyloid-beta accumulation in middle-aged adults.
    J Neurol. 2025;272:670.
    PubMed     Abstract available
    
    
    
43. MAZZEO S, Boveri S, Bortolin E, Bruschi G, et al
    Data-driven subtypes of subjective cognitive decline: neuropsychological profiles, Alzheimer's disease biomarkers, and clinical trajectories.
    J Neurol. 2025;272:669.
    PubMed     Abstract available
    
    
    September 2025
44. SCHMIDT CC, Bardakan MM, Jaeger E, Richter N, et al
    Apraxic deficits predict general cognitive impairment in patients with biomarker-verified Alzheimer's pathology.
    J Neurol. 2025;272:654.
    PubMed     Abstract available
    
    
    
45. ALMEIDA FC, Santos A, Jesus T, Gauthreaux K, et al
    Amygdala-predominant Lewy bodies associate with cognitive decline and amygdala atrophy in Alzheimer's disease neuropathological change.
    J Neurol. 2025;272:629.
    PubMed     Abstract available
    
    
    August 2025
46. ZHANG Q, Lu J, Wang L, Jiao F, et al
    Evaluating (18)F-Florzolotau tau PET for Alzheimer's disease diagnosis with (18)F-Flortaucipir as reference.
    J Neurol. 2025;272:597.
    PubMed     Abstract available
    
    
    
47. MAZZEO S, Crucitti C, Lassi M, Ingannato A, et al
    The HTT gene influences plasma neurofilament light chain and brain metabolism in prodromal Alzheimer's disease.
    J Neurol. 2025;272:588.
    PubMed     Abstract available
    
    
    
48. DENG Z, Huang Z, Ge H, Wang H, et al
    Diagnostic performance of choroid plexus and cerebrospinal fluid space volumes in idiopathic normal pressure hydrocephalus.
    J Neurol. 2025;272:550.
    PubMed     Abstract available
    
    
    June 2025
49. LACZO M, Svacova Z, Lerch O, Martinkovic L, et al
    Spatial navigation deficits in early Alzheimer's disease: the role of biomarkers and APOE genotype.
    J Neurol. 2025;272:438.
    PubMed     Abstract available
    
    
    May 2025
50. ROSENBLOOM M, Schnee A, Nimma S, Lutz H, et al
    Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics.
    J Neurol. 2025;272:394.
    PubMed     Abstract available
    
    
    April 2025
51. MITTLER B, Cambi X, Biskach M, Reisman J, et al
    Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease.
    J Neurol. 2025;272:341.
    PubMed     Abstract available
    
    
    March 2025
52. KORIATH CAM, Rauchmann B, Schoeberl F, Zwergal A, et al
    Vestibular dysfunction: a hidden risk factor for Alzheimer's disease.
    J Neurol. 2025;272:285.
    PubMed     Abstract available
    
    
    
53. ZHANG X, Irish M, Piguet O, Ahmed RM, et al
    Behavioural and cognitive profiles in frontotemporal dementia and Alzheimer's disease: a longitudinal study.
    J Neurol. 2025;272:279.
    PubMed     Abstract available
    
    
    
54. JIANG Y, Jin Z, Wang H, He X, et al
    A dose-response meta-analysis of physical activity and the risk of alzheimer's disease in prospective studies.
    J Neurol. 2025;272:256.
    PubMed     Abstract available
    
    
    
55. ANTONIONI A, Raho EM, Di Lorenzo F, Manzoli L, et al
    Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis.
    J Neurol. 2025;272:252.
    PubMed     Abstract available
    
    
    
56. BUCHHOLZ E, Machule ML, Buthut M, Stefanovski L, et al
    Overlapping presence of beta-amyloid, tau, p-tau, and alpha-synuclein in skin nerve fibers in Alzheimer's disease.
    J Neurol. 2025;272:247.
    PubMed     Abstract available
    
    
    January 2025
57. ZAVARELLA M, Cecchetti G, Rugarli G, Ghirelli A, et al
    Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases.
    J Neurol. 2025;272:168.
    PubMed     Abstract available
    
    
    
58. SARTO J, Esteller-Gauxax D, Guillen N, Falgas N, et al
    Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer's disease diagnosis in a memory clinic cohort.
    J Neurol. 2025;272:160.
    PubMed     Abstract available
    
    
    
59. PRASAD P, Gbadegesin O, Edwards M
    Correction: Evolving management of Alzheimer's disease.
    J Neurol. 2025;272:156.
    PubMed    
    
    
    
60. ZHAO C, Li T, Hao S, Zhao L, et al
    Dysregulation of the molecular clock by blood-borne factors in Alzheimer's disease patients.
    J Neurol. 2025;272:121.
    PubMed     Abstract available
    
    
    December 2024
61. ZILIOLI A, Rosenberg A, Mohanty R, Matton A, et al
    Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting.
    J Neurol. 2024;272:84.
    PubMed     Abstract available
    
    
    
62. RAPOSO PEREIRA F, Chaumon M, Dubois B, Bakardjian H, et al
    Recognition memory decline is associated with the progression to prodromal Alzheimer's disease in asymptomatic at-risk individuals.
    J Neurol. 2024;272:70.
    PubMed     Abstract available
    
    
    
63. ERATNE D, Li QX, Lewis C, Dang C, et al
    Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.
    J Neurol. 2024;272:25.
    PubMed     Abstract available
    
    
    
64. YUAN Y, Zhao G, Zhao Y
    Dysregulation of energy metabolism in Alzheimer's disease.
    J Neurol. 2024;272:2.
    PubMed     Abstract available
    
    
    
65. MUQAKU B, Anderl-Straub S, Werner L, Nagl M, et al
    Contactin proteins in cerebrospinal fluid show different alterations in dementias.
    J Neurol. 2024;271:7516-7524.
    PubMed     Abstract available
    
    
    November 2024
66. PRASAD P, Gbadegesin O, Edwards M
    Evolving management of Alzheimer's disease.
    J Neurol. 2024 Nov 9. doi: 10.1007/s00415-024-12720.
    PubMed    
    
    
    September 2024
67. MITOLO M, Lombardi G, Manca R, Nacmias B, et al
    Association between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: a systematic review.
    J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12674.
    PubMed     Abstract available
    
    
    
68. TABUAS-PEREIRA M, Bernardes C, Duraes J, Lima M, et al
    Exploring first-degree family history in a cohort of Portuguese Alzheimer's disease patients: population evidence for X-chromosome linked and recessive inheritance of risk factors.
    J Neurol. 2024 Sep 5. doi: 10.1007/s00415-024-12673.
    PubMed     Abstract available
    
    
    August 2024
69. CECCHETTI G, Agosta F, Rugarli G, Spinelli EG, et al
    Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer's disease: a real-world study.
    J Neurol. 2024 Aug 22. doi: 10.1007/s00415-024-12631.
    PubMed     Abstract available
    
    
    
70. SHAW SR, Horne KS, Piguet O, Ahmed RM, et al
    Profiles of motivational impairment and their relationship to functional decline in frontotemporal dementia.
    J Neurol. 2024;271:4963-4971.
    PubMed     Abstract available
    
    
    June 2024
71. FOXE D, Irish M, Carrick J, Cheung SC, et al
    Correction to: Visuospatial working memory in behavioural variant frontotemporal dementia: a comparative analysis with Alzheimer's disease using the box task.
    J Neurol. 2024 Jun 21. doi: 10.1007/s00415-024-12483.
    PubMed    
    
    
    
72. LI KY, Chien CF, Huang LC, Lim K, et al
    Exploring the impact of 40 Hz multi-luminaire light exposure in Alzheimer's dementia: insights from a convenient sampling, non-randomized case-control study.
    J Neurol. 2024 Jun 17. doi: 10.1007/s00415-024-12486.
    PubMed     Abstract available
    
    
    May 2024
73. FOXE D, Irish M, Carrick J, Cheung SC, et al
    Visuospatial working memory in behavioural variant frontotemporal dementia: a comparative analysis with Alzheimer's disease using the box task.
    J Neurol. 2024 May 7. doi: 10.1007/s00415-024-12406.
    PubMed     Abstract available
    
    
    
74. CANU E, Rugarli G, Coraglia F, Basaia S, et al
    Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort.
    J Neurol. 2024;271:2716-2729.
    PubMed     Abstract available
    
    
    April 2024
75. WANG S, Zheng X, Huang J, Liu J, et al
    Sleep characteristics and risk of Alzheimer's disease: a systematic review and meta-analysis of longitudinal studies.
    J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12380.
    PubMed     Abstract available
    
    
    
76. ZAMBONI G, Maramotti R, Salemme S, Tondelli M, et al
    Age-specific prevalence of the different clinical presentations of AD and FTD in young-onset dementia.
    J Neurol. 2024 Apr 21. doi: 10.1007/s00415-024-12364.
    PubMed     Abstract available
    
    
    
77. GUILOFF AE, Rudge P
    Amyloid antibody therapy for early-stage Alzheimer's disease: a critical review of three recent trials.
    J Neurol. 2024 Apr 13. doi: 10.1007/s00415-024-12361.
    PubMed    
    
    
    
78. LAVROVA A, Pham NTT, Vernon CJ, Carlos AF, et al
    A multimodal clinical diagnostic approach using MRI and (18)F-FDG-PET for antemortem diagnosis of TDP-43 in cases with low-intermediate Alzheimer's disease neuropathologic changes and primary age-related tauopathy.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12312.
    PubMed     Abstract available
    
    
    
79. MENDES AJ, Ribaldi F, Lathuiliere A, Ashton NJ, et al
    Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort.
    J Neurol. 2024;271:2053-2066.
    PubMed     Abstract available
    
    
    
80. O'CONNOR A, Lyons S, Finnegan M, Walsh J, et al
    Expanding the phenotype of psychiatric-onset prodromal dementia with Lewy bodies.
    J Neurol. 2024;271:2125-2128.
    PubMed    
    
    
    
81. SARTO J, Esteller-Gauxax D, Tort-Merino A, Guillen N, et al
    Impact of demographics and comorbid conditions on plasma biomarkers concentrations and their diagnostic accuracy in a memory clinic cohort.
    J Neurol. 2024;271:1973-1984.
    PubMed     Abstract available
    
    
    March 2024
82. LANGERSCHEIDT F, Wied T, Al Kabbani MA, van Eimeren T, et al
    Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.
    J Neurol. 2024 Mar 30. doi: 10.1007/s00415-024-12314.
    PubMed     Abstract available
    
    
    
83. SINGH NA, Graff-Radford J, Machulda MM, Carlos AF, et al
    Atypical Alzheimer's disease: new insights into an overlapping spectrum between the language and visual variants.
    J Neurol. 2024 Mar 29. doi: 10.1007/s00415-024-12297.
    PubMed     Abstract available
    
    
    
84. PENG M, Yuan S, Lu D, Ling Y, et al
    Dietary inflammatory index, genetic susceptibility and risk of incident dementia: a prospective cohort study from UK biobank.
    J Neurol. 2024;271:1286-1296.
    PubMed     Abstract available
    
    
    February 2024
85. SUBOTIC A, Gee M, Nelles K, Ba F, et al
    Gray matter loss relates to dual task gait in Lewy body disorders and aging.
    J Neurol. 2024;271:962-975.
    PubMed     Abstract available
    
    
    January 2024
86. HUANG M, Landin-Romero R, Matis S, Dalton MA, et al
    Longitudinal volumetric changes in amygdala subregions in frontotemporal dementia.
    J Neurol. 2024 Jan 24. doi: 10.1007/s00415-023-12172.
    PubMed     Abstract available
    
    
    
87. GENG C, Meng K, Tang Y
    Identifying the mediating role of inflammation on the relationship between socioeconomic status and Alzheimer's disease: a Mendelian randomization analysis and mediation analysis.
    J Neurol. 2024 Jan 22. doi: 10.1007/s00415-023-12176.
    PubMed     Abstract available
    
    
    
88. HENNEY AE, Gillespie CS, Alam U, Hydes TJ, et al
    High intake of ultra-processed food is associated with dementia in adults: a systematic review and meta-analysis of observational studies.
    J Neurol. 2024;271:198-210.
    PubMed     Abstract available
    
    
    December 2023
89. MASSA F, Martinuzzo C, Gomez de San Jose N, Pelagotti V, et al
    Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease.
    J Neurol. 2023 Dec 29. doi: 10.1007/s00415-023-12154.
    PubMed     Abstract available
    
    
    
90. RONAT L, Hanganu A, Chylinski D, Van Egroo M, et al
    Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12131.
    PubMed     Abstract available
    
    
    November 2023
91. ST-GEORGES MA, Wang L, Chapleau M, Migliaccio R, et al
    Social cognition and behavioral changes in patients with posterior cortical atrophy.
    J Neurol. 2023 Nov 30. doi: 10.1007/s00415-023-12089.
    PubMed     Abstract available
    
    
    
92. PEREZ-MILLAN A, Borrego-Ecija S, Falgas N, Junca-Parella J, et al
    Cortical thickness modeling and variability in Alzheimer's disease and frontotemporal dementia.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12087.
    PubMed     Abstract available
    
    
    
93. VRILLON A, Ashton NJ, Karikari TK, Gotze K, et al
    Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
    J Neurol. 2023 Nov 11. doi: 10.1007/s00415-023-12066.
    PubMed     Abstract available
    
    
    September 2023
94. STAM D, Rosseel S, De Winter FL, Van den Bossche MJA, et al
    Facial expression recognition deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic investigation of effects of phenotypic variant, task modality, geographical region and symptomatic specificity.
    J Neurol. 2023 Sep 6. doi: 10.1007/s00415-023-11927.
    PubMed     Abstract available
    
    
    
95. CHAN E, Bonifacio GB, Harrison C, Banerjee G, et al
    Domain-specific neuropsychological investigation of CAA with and without intracerebral haemorrhage.
    J Neurol. 2023 Sep 6. doi: 10.1007/s00415-023-11977.
    PubMed     Abstract available
    
    
    
96. DAMSGAARD L, Janbek J, Laursen TM, Waldemar G, et al
    Healthcare utilization prior to a diagnosis of young-onset Alzheimer's disease: a nationwide nested case-control study.
    J Neurol. 2023 Sep 5. doi: 10.1007/s00415-023-11974.
    PubMed     Abstract available
    
    
    July 2023
97. PENA-BAUTISTA C, Alvarez-Sanchez L, Ferrer-Cairols I, Garcia-Valles L, et al
    Assessment of COVID-19 lockdown effect on early Alzheimer Disease progression.
    J Neurol. 2023 Jul 28. doi: 10.1007/s00415-023-11899.
    PubMed     Abstract available
    
    
    
98. MIZUTANI Y, Ohdake R, Tatebe H, Higashi A, et al
    Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease.
    J Neurol. 2023 Jul 22. doi: 10.1007/s00415-023-11875.
    PubMed     Abstract available
    
    
    
99. SAW AM, Hrastelj J, Robertson NP
    Path from discovery to recovery: therapeutic and diagnostic advances in Alzheimer's dementia.
    J Neurol. 2023 Jul 3. doi: 10.1007/s00415-023-11840.
    PubMed    
    
    
    June 2023
100. KUCIKOVA L, Zeng J, Munoz-Neira C, Muniz-Terrera G, et al
     Genetic risk factors of Alzheimer's Disease disrupt resting-state functional connectivity in cognitively intact young individuals.
     J Neurol. 2023 Jun 26. doi: 10.1007/s00415-023-11809.
     PubMed     Abstract available
     
     
     April 2023
101. LING Y, Yuan S, Huang X, Tan S, et al
     The association of night shift work with the risk of all-cause dementia and Alzheimer's disease: a longitudinal study of 245,570 UK Biobank participants.
     J Neurol. 2023 Apr 6. doi: 10.1007/s00415-023-11672.
     PubMed     Abstract available
     
     
     
102. FERRUCCI R, Cuffaro L, Capozza A, Rosci C, et al
     Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19.
     J Neurol. 2023;270:1823-1834.
     PubMed     Abstract available
     
     
     
103. TAYLOR NL, Shine JM
     A whole new world: embracing the systems-level to understand the indirect impact of pathology in neurodegenerative disorders.
     J Neurol. 2023;270:1969-1975.
     PubMed     Abstract available
     
     
     
104. CONSTANTINIDES VC, Tentolouris-Piperas V, Paraskevas GP, Pyrgelis ES, et al
     Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies.
     J Neurol. 2023;270:2059-2068.
     PubMed     Abstract available
     
     
     March 2023
105. SEMENKOVA A, Piguet O, Johnen A, Schroeter ML, et al
     The Behavioural Dysfunction Questionnaire discriminates behavioural variant frontotemporal dementia from Alzheimer's disease dementia and major depressive disorder.
     J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11666.
     PubMed     Abstract available
     
     
     
106. FILIPPI M, Cecchetti G, Cagnin A, Marra C, et al
     Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline.
     J Neurol. 2023 Mar 9. doi: 10.1007/s00415-023-11642.
     PubMed     Abstract available
     
     
     February 2023
107. JISKOOT LC, Russell LL, Greaves CV, van Schaik E, et al
     Addition of the FTD Module to the Neuropsychiatric Inventory improves classification of frontotemporal dementia spectrum disorders.
     J Neurol. 2023 Feb 22. doi: 10.1007/s00415-023-11596.
     PubMed     Abstract available
     
     
     January 2023
108. CRETIN B, Philippi N, Bousiges O, Blanc F, et al
     Transient epileptic amnesia: a retrospective cohort study of 127 cases, including CSF amyloid and tau features.
     J Neurol. 2023 Jan 30. doi: 10.1007/s00415-023-11576.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum